Skip to NavigationSkip to content

News

0
Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and key secondary endpoints...
0
Daiichi Sankyo show low CV events and bleeding in NVAF patients on Lixiana
Daiichi Sankyo have announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients treated...
0
Shionogi reports positive results for cefiderocol in pneumonia
Shionogi has reported positive data from a trial of its investigational antibiotic cefiderocol which is already under regulatory review in the US and...
0
Roche's Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris
Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the treatment...
>> More News Stories

Features

On to greener pastures?

In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores the history of...

>> More Features
>> More News Stories